For media inquiries, please contact Erich Horsley at: media@samumed.com

2020

Date	Title
Dec 01	Darrin M. Beaupre, M.D., Ph.D. joins Samumed as Chief Medical Officer, Oncology
Nov 17	Samumed Chief Medical Officer, Dr. Yusuf Yazici, Discusses Lorecivivint on the Podcast “ACR on Air”
Jun 01	Michael White, Ph.D. joins Samumed as Chief Scientific Officer
May 22	Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis
Jan 23	Rheumatology Advisor: Effect of Intra-Articular Treatment on Patient-Reported Outcomes in Knee Osteoarthritis
Jan 21	DDNews: Meeting a new mechanism
Jan 21	BioSpace: Getting to the Root of the Disease: Developing Drugs Against the Hard-to-Target Wnt Pathway

2019

Date	Title
Nov 27	Healio Rheumatology: Lorecivivint yields improved patient-reported outcome scores in knee OA
Nov 14	HCPLive: Lorecivivint a Potential Novel Treatment for Knee Osteoarthritis
Nov 13	Samumed Presents Safety Data Analysis of Lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting
Oct 02	Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors
Sep 12	DDNews: A strong showing for SM07883
Aug 15	FierceBiotech: In Conversation with Samumed CEO Osman Kibar: Drugging Wnt, Restoring Youth and Unconventional Capital
Aug 14	Xtalks: Tackling Multiple Pathways with One Alzheimer’s Drug
Aug 05	Technology Networks: Therapeutically Targeting DYRK1A in Alzheimer’s Disease
Jul 24	Alzheimer's News Today: Samumed’s SM07883 Can Prevent Tau-Mediated Neuroinflammation, Neurodegeneration in Mice, Study Shows
Jul 18	Samumed Announces Publication of Preclinical Data Demonstrating That SM07883 is a Potential Treatment for Alzheimer’s Disease
Jun 19	Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial of Lorecivivint for the Treatment of Knee Osteoarthritis
May 02	Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis
Apr 10	Samumed Announces Multiple Presentations at the 19th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Apr 10	Alzheimer's News Today: Phase 1 Trial of Alzheimer’s Candidate SM07883 Doses First Participant
Apr 04	Samumed Doses First Subject in Phase 1 Trial of SM07883, a Potential Treatment for Alzheimer’s Disease
Mar 27	The Rheumatologist: SM04690 Promising for Knee OA
Mar 07	Samumed to Present Clinical Data on SM04690 at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
Jan 29	Samumed to Present Novel Biological Targets of SM04690 for Treatment of Knee Osteoarthritis
Jan 03	Samumed Granted Orphan Drug Designation for SM08502 for the Treatment of Pancreatic Cancer

2018

Date	Title
Nov 19	Samumed Doses First Subject in Phase 2/3 Trial of SM04554 for the Treatment of Androgenetic Alopecia
Nov 05	Samumed Announces Multiple Presentations at 6th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD)
Oct 24	Samumed Phase 2b Trial in Knee Osteoarthritis Meets Primary Endpoints
Oct 18	Samumed to Present Preclinical Data on SM07883 at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Congress
Oct 16	Samumed to Present Data from Phase 2b Trial of SM04690 for Treatment of Knee Osteoarthritis at 2018 American College of Rheumatology (ACR) Annual Meeting
Oct 15	Samumed Announces Sponsorship of Knee Osteoarthritis Registry Study
Sep 17	Samumed and United Therapeutics Announce North American License Agreement for Samumed’s IPF Drug Candidate
Aug 06	Samumed Closes on $438 Million in Equity Financing
Jul 27	Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer’s Association International Conference® (AAIC®)
Jul 17	Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer’s Disease Candidate, at the Alzheimer’s Association International Conference® (AAIC®) 2018
Jun 29	Samumed Announces Presentation of Clinical Data Analysis on SM04690 for Treatment of Knee Osteoarthritis at International Workshop on Osteoarthritis Imaging (IWOAI) 2018 Conference
Jun 20	Samumed Presents Clinical and Preclinical Data at European League Against Rheumatism (EULAR) 2018 Annual Congress
May 31	Samumed to Present Data on Multiple Product Candidates in Five Presentations at The Orthobiologic Institute (TOBI) 2018 Annual Symposium
May 03	Scrip Pharma Intelligence: Samumed CMO Hopes to Reach Drug Approvals via the Wnt Pathway

2017

Date	Title
Oct 31	Samumed Initiates Phase 1b Trial of SM04755 for Treatment of Psoriasis
Oct 24	Samumed Announces 52-week Phase 2 Osteoarthritis Data Supporting the Potential of SM04690 as a Disease Modifying Drug
Oct 05	Nature Reviews Rheumatology: Wnt Inhibitor Shows Potential as a DMOAD
Jul 27	Samumed Successfully Completed 52-week Phase 2 Study for Treatment of Osteoarthritis of the Knee
Jul 25	PulmonaryFibrosisNews.com: FDA Grants Orphan Drug Designation to Samumed’s Investigational SM04646 for IPF Treatment
Jul 24	Samumed Receives Orphan Drug Designation from FDA for SM04646 as a Treatment for Idiopathic Pulmonary Fibrosis (IPF)
Jul 21	Samumed Successfully Completes Phase 1 Study for Potential Topical Treatment for Chronic Tendinopathy
Jul 20	Samumed and IHS Markit Present Analysis of Medicare Claims Data for Knee OA
Jul 17	Samumed Successfully Completed Phase 1 Study for the Potential Treatment of Idiopathic Pulmonary Fibrosis
Jun 20	Samumed Selected for Four Presentations at European League Against Rheumatism (EULAR) 2017 Annual Meeting
Jun 20	Pharmaceutical-Technology.com: EULAR 2017: Osteoarthritis Pipeline Product Shows Promise
Apr 02	BusinessInsider.com: A $12 Billion Startup You've Probably Never Heard Wants to Cure Baldness and Smooth Out Your Wrinkles
Mar 15	Samumed’s CEO Presents at Near Future Summit 2017
Mar 06	Samumed Presented Data on Increases in Hair Follicles Observed in Its Phase 2 Biopsy Study for a Potential Treatment of Androgenetic Alopecia (AGA) at Annual Meeting of the American Academy of Dermatology (AAD)

2016

Date	Title
Nov 01	Samumed Selected for Seven Presentations in Five Therapeutic Areas at American College of Rheumatology 2016 Annual Meeting
May 05	CNBC Interview with Samumed's CEO
Apr 13	Forbes.com: The Forbes Global Game Changers List: Bezos, Zuckerberg And More Business Leaders Transforming The World
Apr 04	Samumed presents at the 2016 World Congress of the Osteoarthritis Research Society International (OARSI)
Mar 07	Samumed presents at the annual meeting of the American Academy of Dermatology (AAD) Safety and Efficacy results from its Phase 2 androgenetic alopecia (AGA) trial
Mar 05	Forbes.com: Experimental Drug Shows Early Promise In Treating Male Baldness

2015

Date	Title
Nov 18	Samumed, LLC to announce clinical data on potential treatment of androgenetic alopecia at the World Congress for Hair Research
Nov 12	U.S. Congressman Scott Peters visits the Samumed corporate office
Nov 09	Samumed, LLC Announces Successful Modulation Of The Wnt Pathway For Potential Cartilage Regeneration
Nov 06	Samumed Begins Enrollment In A Phase II Clinical Trial For The Treatment Of Osteoarthritis (OA) Of The Knee Using A Novel Wnt Pathway Modulator
Nov 03	Samumed, LLC To Announce Potential Disease Modifying Treatment Of Osteoarthritis At American College of Rheumatology (ACR) Annual Meeting

web stats